Introduction: Long-term management of type 2 diabetes (T2D) and sustaining glycemic control remains a challenge and crucial for reducing clinical complications and subsequent economic costs. This study followed glycemic outcomes, average blood glucose (BG avg) and high readings ratio, over 3 years in persons using a digital therapeutic platform.

Objective: To investigate blood glucose (BG) levels in persons with T2D in high-risk who used a digital therapeutic platform to manage their BG levels over three years. Additionally, to compare outcomes between consistently engaged users over 3 years versus less consistent population.

Method: A retrospective data analysis was performed on users with T2D in high-risk (baseline BG avg>169 mg/dL in month1; equivalent to A1C 7.5) who activated between 2017-2020 and measured their BG using Dario platform over 3 consecutive years (months 1,6,12,24 and 36). The ratios assessed were BG avg and high BG readings ratio (>180 mg/dL). Digital engagement was assessed by additional parameters including measurement type (fasting/premeal/post meal/bedtime), carbs intake, meal type, and physical activity alongside glucose measurement.

Results: A group of 1,239 users significantly reduced their BG avg consistently over 3 years by 15.6% (179±55 vs. 212±42) (p<0.05) and high readings ratio by 39% (p<0.05). A subset of users completed at least one engagement type following months 12, 24, and 36 (N=433) demonstrated significantly greater reductions versus the complementary group (N=806): BG avg by 18.8% (172±51 vs. 212±45) and high readings ratio by 45% (p<0.05).

Conclusion: A digital diabetes platform has the potential to affect and sustain glycemic control improvements over 3 years. Moreover, it appears highly likely that engagement to app features in chronic condition management may help users with T2D consistently pay attention to their life behaviors to maintain better clinical outcomes.

Disclosure

Y.Hershcovitz: Employee; DarioHealth Corp. N.Yaniv: Employee; DarioHealth Corp. S.Budman: Employee; DarioHealth Corp. O.Manejwala: Employee; DarioHealth Corp., Stock/Shareholder; DarioHealth Corp.

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.